// App-Quantinova.ai

e11615 : A novel approach to assess Her2-status of circulating tumour cells (CTCs) using the automated BioMarQ System.

Researchers

Presenter

  • Elisabeth Katharina Trapp

Principal Investigators

  • Thomas W. P. Friedl

  • Marianna Alunni-Fabbroni

  • Wolfgang Janni

  • Ulrich Andergassen

  • Aurelia Vattai

  • Tanja N. Fehm

  • Volkmar Mueller

  • Amelie Schramm

  • Bernadette Jaeger

  • Brigitte Kathrin Rack

  • Leonie Majunke

  • Jan Keij

Medical Centers

  • University Hospital, Duesseldorf, Germany

  • LMU Munich-Innenstadt, Munich, Germany

  • Department of Gynecology and Obstetrics University Ulm, Ulm, Germany

  • Department of Gynecology and Obstetrics Ludwig-MaximiliansUniversity, Munich, Germany

  • I. Universitaetsfrauenklinik, Hebertshausen, GermanyUniversitaetsklinikum Ulm, Ulm, GermanyKlinikum der Universitaet Muenchen ? Klinik und Poliklinik fuer Frauenheilkunde und Geburtshilfe, Munich, Germany

  • University Medical Center Hamburg Eppendorf, Hamburg, Germany

  • Department of Gynecology and Obstetrics University Ulm, Ulm, Germany

  • Department of Gynaecology and Obstetrics, University Hospital of Ludwig-Maximilians-University Munich, Munich, Germany

  • Universitatsklinikum Ulm, Ulm, Germany

  • Klinikum der Universitaet Muenchen ? Klinik und Poliklinik fuer Frauenheilkunde und Geburtshilfe Campus Innenstadt ? Maistrasse 11, Munich, Germany

  • Research and Development, Janssen Diagnostics, Huntingdon Valley, PA

Locations

  • United States

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Circulating tumor cells

  • erb-b2 receptor tyrosine kinase 2

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved